Affordable Access

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.

Authors
  • Svenson, M1
  • Geborek, P
  • Saxne, T
  • Bendtzen, K
  • 1 Institute for Inflammation Research, Rigshospitalet National University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Type
Published Article
Journal
Rheumatology (Oxford, England)
Publication Date
December 2007
Volume
46
Issue
12
Pages
1828–1834
Identifiers
PMID: 18032541
Source
Medline
License
Unknown

Abstract

Specific and neutralizing anti-infliximab antibodies develop in RA patients treated with infliximab, and that low trough levels of functional infliximab are associated with the presence of such antibodies. The most sensitive antibody assay involved binding to soluble and intact infliximab. Assessments of bioavailability and immunogenicity of anti-TNF biologicals may be used to optimize dose regimens and prevent prolonged use of inadequate therapy.

Report this publication

Statistics

Seen <100 times